MP15-Enfermedades Hepaticas y Cáncer Colorectal

Contribution of sociodemographic, occupational, lifestyle and dietary characteristics to the oxidative stress microenvironment in adipose tissue

ENVIRONMENTAL RESEARCH, 2019;

FI:5,026; D1

Exploring the radiosensitizing potential of magnetotherapy: a pilot study in breast cancer cells

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2019;

FI:2,266; D1

Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells

EXPERIMENTAL EYE RESEARCH, 2019;

FI:2,998; Q1

An Overview of the Polymorphisms of Circadian Genes Associated With Endocrine Cancer

FRONTIERS IN ENDOCRINOLOGY, 2019;

FI:3,634; Q2

Chemotherapy-induced liver injury in children

ANALES DE PEDIATRIA, 2019;

FI:1,166; Q3

The SELGIFS data challenge: generating synthetic observations of CALIFA galaxies from hydrodynamical simulations

MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY, 2018;

FI:5,194; Q1

Admission, discharge and triage guidelines for paediatric intensive care units in Spain

ANALES DE PEDIATRIA, 2018;

FI:1,318; Q3

Admission, discharge and triage guidelines for paediatric intensive care units in Spain

MEDICINA INTENSIVA, 2018;

FI:1,755; Q4

Prevalence of markers of celiac disease in Colombian children with diabetes mellitus type 1

COLOMBIA MEDICA, 2018;

FI:0,767; Q4

Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C

JOURNAL OF HEPATOLOGY, 2018;

FI:15,04; D1

Ethical attitudes of intensive care paediatricians as regards patients with spinal muscular atrophy type 1

ANALES DE PEDIATRIA, 2017;

FI:1,14; Q3

Hepatic hematoma after ERCP: two new case reports

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2017;

FI:1,401; Q4

Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment

WORLD JOURNAL OF GASTROENTEROLOGY, 2017;

FI:3,365; Q2

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

WORLD JOURNAL OF GASTROENTEROLOGY, 2017;

FI:3,365; Q2

Spatio-temporal monitoring by ground-based and air- and space-borne lidars of a moderate Saharan dust event affecting southern Europe in June 2013 in the framework of the ADRIMED/ChArMEx campaign

AIR QUALITY ATMOSPHERE AND HEALTH, 2017;

FI:3,184; Q2

High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods (vol 53, pg 219, 2015)

JOURNAL OF CLINICAL MICROBIOLOGY, 2016;

FI:3,631; Q2

Effects of manual therapy on treatment duration and motor development in infants with severe nonsynostotic plagiocephaly: a randomised controlled pilot study

CHILDS NERVOUS SYSTEM, 2016;

FI:1,08; Q3

Repercussions of plagiocephaly on posture, muscle flexibility and balance in children aged 3-5years old

JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2016;

FI:1,477; Q3

Drug utilization pattern in children and off-label use of medicines in a pediatric intensive care unit

MEDICINA INTENSIVA, 2016;

FI:1,193; Q4

Contribution of Persistent Organic Pollutant Exposure to the Adipose Tissue Oxidative Microenvironment in an Adult Cohort: A Multipollutant Approach

ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2016;

FI:5,393; D1

Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection

GENES AND IMMUNITY, 2015;

FI:2,913; Q2

Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

WORLD JOURNAL OF GASTROENTEROLOGY, 2015;

FI:2,369; Q3

Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015;

FI:2,253; Q3

HEPATOTOXICITY FROM THE CONSUMPTION OF HERBALIST PRODUCTS BY A PAEDIATRIC POPULATION

NUTRICION HOSPITALARIA, 2015;

FI:1,04; Q4

Does the presence of contrast material in the digestive tract mean prior barium ingestion?

GASTROENTEROLOGIA Y HEPATOLOGIA, 2015;

FI:0,838; Q4

Relación de las Poblaciones de Pre-Adipocitos y el Infiltrado Inmunológico del Tejido Adiposo Con la Enfermedad del Hígado Graso No Alcohólico en Obesos Mórbidos.

Financiador: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

Número de expediente: PI-0515-2014

Tiempo de ejecución: 31/07/2015 - 30/09/2017

IP: FRANCISCO JAVIER SALMERON ESCOBAR

Validation study of biomarkers associated both with increased risk of mother-to-child HCV transmission and with increased risk of persistent HCV infection in children vertically transmitted

Financiador: GILEAD SCIENCES INTERNATIONAL LTD.

Número de expediente: GLD15-00307

Tiempo de ejecución: 01/03/2016 - 01/03/2017

IP: FRANCISCO JAVIER SALMERON ESCOBAR

Relación de las poblaciones de pre-adipocitos y el infiltrado inmunológico del tejido adiposo con la enfermedad del hígado graso no alcohólico en obesos mórbidos

Financiador: INSTITUTO DE SALUD CARLOS III

Número de expediente: PI15/01361

Tiempo de ejecución: 01/01/2016 - 31/12/2018

IP: FRANCISCO JAVIER SALMERON ESCOBAR

Caracterización epidemiológica, inmunogenética ymetabolómica de la hepatotoxicidad en la población pediátrica

Financiador: INSTITUTO DE SALUD CARLOS III

Número de expediente: PI17/01989

Tiempo de ejecución: 01/01/2018 - 31/12/2020

IP: ESTHER OCETE HITA

Estudio de la evolución de la heterogeneidad tumoral derivada de células madre tumorales y células inmunes infiltradas durante el tratamiento en cáncer de recto y su relación con la recidiva.

Financiador: INSTITUTO DE SALUD CARLOS III

Número de expediente: PI18/01947

Tiempo de ejecución: 01/01/2019 - 31/12/2021

IP: FRANCISCO JAVIER SALMERON ESCOBAR

Estudio multicentrico, aleatorizado, con doble enmascaramiento y controlado con placebo de la eficacia y seguridad de LJPC-501 en pacientes pediatrico de >2 a 17 años de edad con hipotension resistente a las catecolaminas asociadas a shock distributivo

Financiador: LA JOLLA PHARMACEUTICAL COMPANY

Tipo de prueba: ENSAYO CLINICO COMERCIAL

Tiempo de ejecución: 04/12/2018 - 30/05/2021

IP: ESTHER OCETE HITA